Table 3.
Preventive and acute migraine-related treatment patterns during the baseline and study periods
| Patients with chronic migraine (N = 1034) | ||
|---|---|---|
| Baseline period | Study period | |
| Number of prior preventive treatment failures,a mean ± SD [median] | 5.20 ± 4.49 [4] | – |
| Number of preventive treatments,b,c mean ± SD [median] | 2.00 ± 1.34 [2] | 2.02 ± 1.36 [2] |
| Number of acute treatments,d mean ± SD [median] | 2.00 ± 1.43 [2] | 2.25 ± 1.63 [2] |
| Initiation of new preventive treatment during study period,c N (%) | – | 160 (15.5%) |
| Initiation of new acute treatment during study period,d N (%) | – | 250 (24.3%) |
| Discontinuation of preventive treatment from baseline,e N (%) | – | 300 (32.8%) |
| Discontinuation of acute treatment from baseline,f N (%) | – | 250 (27.0%) |
| Most commonly reported preventive treatment types, N (%) | ||
| Antiepileptic agents | 506 (48.9%) | 501 (48.5%) |
| Antidepressants | 494 (47.8%) | 488 (47.2%) |
| Botulinum toxin | 438 (42.4%) | 427 (41.3%) |
| Antihypertensive agents | 309 (29.9%) | 307 (29.7%) |
| Other migraine preventative agents | 83 (8.0%) | 82 (7.9%) |
| Anti-CGRP (excluding erenumab) | 0 (0.0%) | 39 (3.8%) |
| Most commonly reported acute treatment types, N (%) | ||
| Triptans | 709 (68.6%) | 732 (70.8%) |
| NSAIDs | 409 (39.6%) | 453 (43.8%) |
| Muscle relaxants | 285 (27.6%) | 314 (30.4%) |
| Opioids | 129 (12.5%) | 121 (11.7%) |
| Ergotamines | 65 (6.3%) | 78 (7.5%) |
| Barbiturates | 28 (2.7%) | 33 (3.2%) |
| Other | 11 (1.1%) | 15 (1.5%) |
Anti-CGRP anti-calcitonin gene-related peptide, NSAID non-steroidal anti-inflammatory drug
aAssessed at any time prior to erenumab initiation; the number of treatment failures prior to care at participating centers may be underreported
bNumber of preventive treatments excluded erenumab
cAssessed among 1032 patients with treatment information in both baseline and study periods
dAssessed among 1027 patients with treatment information in both baseline and study periods
eAssessed among 916 patients with known discontinuation status of baseline treatments
fAssessed among 925 patients with known discontinuation status of baseline treatments